

Technical Information

NT-proANP (1-98)



Cat. No.:	BI-20892
Tests:	96
Method:	ELISA
Range:	0 – 10 nmol/l
LLOQ:	0.05 nmol/l (STD2 0.63 pmol/l)
Incubation time:	3 h / 30 min
Sample volume:	10 µl
Sample type:	Serum, EDTA/Heparin plasma, urine, cc supernatant
Sample preparation:	Centrifuge freshly collected blood as soon as possible Store centrifuged samples at -20°C for longer storage. Samples are stable up to 3 freeze and thaw cycles (for serum samples only 2 F/T cycles). Hemolyzed or lipemic samples may cause erroneous results.

Reference values: Median EDTA plasma (n=53): 1.45 nmol/l

Species: Human. Cross-reacts with: rat, mouse (for pre-clinical studies)

Intended use:

Atrial natriuretic peptide is synthesized in atrial myocytes and is stored in secretory granules as a 126 amino acid prohormone. The most important stimulus for the release of the hormone into circulation is stretch of the myocyte fibres. On release the prohormone is split into equimolar amounts of the highly biologically active proANP (99-126), also known as α -ANP, and the N-terminal part proANP (1-98). α -ANP is rapidly cleared from the circulation with a half life of 3-4 minutes. proANP (1-98) has a much longer half-life (60-120 min) which leads to significantly higher concentrations in blood compared to α -ANP. Thus, circulating levels of proANP (1-98) are less sensitive to the pulsatile secretion of ANP and may better reflect chronic levels of ANP secretion than the rapidly fluctuating levels of α -ANP. proANP is discussed as valuable marker for e.g. sepsis (Increased plasma levels of NT-proANP and NT proBNP as markers of cardiac dysfunction in septic patients. Hoffmann U. et al., Clin. Lab. 2005;51 (7-8):373-9), or risk stratification in heart failure (Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Berger R. et al, European Journal of Clinical Investigation, 2005, 35 (1), 24-31)

Intended applications:

- Research studies on heart failure (LVD, CHF etc.)
- Risk assessment in heart failure patients
- Research studies on heart transplanted patients
- Risk assessment in MI patients with normal NT-proBNP levels
- Drug therapy monitoring in cardiovascular disease
- Monitoring of cardiac resynchronisation therapy

For further information please contact / Für weitere Informationen wenden Sie sich bitte an /
Pour plus d'informations, veuillez contacter:

www.tecomedical.com



A EUROBIO SCIENTIFIC COMPANY

Switzerland / Headquarters

TECOmedical AG
Gewerbstrasse 10
4450 Sissach
Phone +41 61 985 81 00
Fax +41 61 985 81 09
Mail info@tecomedical.com

Germany

TECOmedical GmbH
Wasserbreite 57
32257 Bünde
Phone +49 52 23 985 99 99
Fax +49 52 23 985 99 98
Mail info@tecomedical.com

Benelux

TECOmedical Benelux BV
Prins Willem-Alexanderlaan 301
7311 SW Apeldoorn, The Netherlands
Phone +31 30 307 87 30
Fax +31 30 307 49 39
Mail benelux@tecomedical.com

Austria

TECOmedical AG
Phone 0800 20 40 66
Fax 0800 20 40 55
Mail info@tecomedical.com